yibeinoside A

CAS No. 98985-24-1

yibeinoside A( Sinpeinine-3-O-β-glucoside )

Catalog No. M21473 CAS No. 98985-24-1

Yibeinoside A is an alkaloid from Fritillaria pallidiflora.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 174 In Stock
10MG 255 In Stock
25MG 430 In Stock
50MG 621 In Stock
100MG 883 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    yibeinoside A
  • Note
    Research use only, not for human use.
  • Brief Description
    Yibeinoside A is an alkaloid from Fritillaria pallidiflora.
  • Description
    Yibeinoside A is an alkaloid from Fritillaria pallidiflora.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Sinpeinine-3-O-β-glucoside
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    98985-24-1
  • Formula Weight
    575.8
  • Molecular Formula
    C33H53NO7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [H][C@@]12CC[C@@]3([H])[C@@H](C)[C@]4([H])CC[C@H](C)CN4C[C@@]3([H])[C@]1([H])C[C@@]1([H])[C@@]2([H])CC(=O)[C@@]2([H])C[C@H](CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
  • Chemical Name
    Cevan-6-one 3-(beta-D-glucopyranosyloxy)- (3beta5alpha17beta)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • u-Conotoxin GIIIA

    u-Conotoxin GIIIA

  • Diphyllin O-glucosid...

    Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC50 of 6.51 μM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo.

  • Frovocimab

    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin/Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia.